Loading
Obesity / Semaglutide · Phase 3 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial comparing semaglutide to placebo in children and adolescents with obesity, powered to measure change in BMI over 68 weeks. No results are posted in this registry record; the study is active but no longer recruiting, with planned follow-up to 132 weeks. Outcomes and efficacy remain unreported at this time.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity; age from 6 Years; to 18 Years. Intervention: Group Kids; Group Teens. Compared with: DRUG: Placebo. n = 210. 56 sites across 10 countries.
This is a Phase 3 randomized controlled trial comparing semaglutide to placebo in children and adolescents with obesity, powered to measure change in BMI over 68 weeks. No results are posted in this registry record; the study is active but no longer recruiting, with planned follow-up to 132 weeks. Outcomes and efficacy remain unreported at this time.
Primary outcome is BMI change at 68 weeks; longer-term efficacy and safety outcomes not reported here.
The source did not state who this applies to in practice.
This is a Phase 3 registry record with no reported results; the study is active but not recruiting, so outcomes remain unreported in this source.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05726227). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 210 participants (ESTIMATED). Conditions: Obesity. Interventions: DRUG: Semaglutide; DRUG: Placebo. Primary outcome measures: Group Kids: Change in body mass index (BMI) , From baseline (week 0) to week 68. Brief summary: This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.